These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254 [TBL] [Abstract][Full Text] [Related]
45. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Morris PG; Ulaner GA; Eaton A; Fazio M; Jhaveri K; Patil S; Evangelista L; Park JY; Serna-Tamayo C; Howard J; Larson S; Hudis CA; McArthur HL; Jochelson MS Cancer; 2012 Nov; 118(22):5454-62. PubMed ID: 22517371 [TBL] [Abstract][Full Text] [Related]
46. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT. Yoneyama T; Tateishi U; Endo I; Inoue T Eur J Radiol; 2014 Oct; 83(10):1734-9. PubMed ID: 25043494 [TBL] [Abstract][Full Text] [Related]
47. The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomography reduce the need for invasive procedures? Metin M; Citak N; Sayar A; Pekcolaklar A; Melek H; Kök A; Gurses A J Thorac Oncol; 2011 Oct; 6(10):1713-9. PubMed ID: 21716145 [TBL] [Abstract][Full Text] [Related]
48. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539 [TBL] [Abstract][Full Text] [Related]
49. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774 [TBL] [Abstract][Full Text] [Related]
50. Whole body PET/CT for initial staging of choroidal melanoma. Finger PT; Kurli M; Reddy S; Tena LB; Pavlick AC Br J Ophthalmol; 2005 Oct; 89(10):1270-4. PubMed ID: 16170114 [TBL] [Abstract][Full Text] [Related]
51. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Chen J; Cheong JH; Yun MJ; Kim J; Lim JS; Hyung WJ; Noh SH Cancer; 2005 Jun; 103(11):2383-90. PubMed ID: 15856477 [TBL] [Abstract][Full Text] [Related]
52. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors]. Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099 [TBL] [Abstract][Full Text] [Related]
53. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related]
54. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924 [TBL] [Abstract][Full Text] [Related]
56. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906 [TBL] [Abstract][Full Text] [Related]
57. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214 [TBL] [Abstract][Full Text] [Related]
58. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052 [TBL] [Abstract][Full Text] [Related]
59. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113 [TBL] [Abstract][Full Text] [Related]
60. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]